Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

China’s Box Office Snaps Five-Week Decline on Big Domestic Openings
In Depth: The Role of China’s Newly Created National Data Bureau
China’s Box Office Snaps Five-Week Decline on Big Domestic Openings
In Depth: The Role of China’s Newly Created National Data Bureau
China’s Scandal-Plagued Semiconductor ‘Big Fund’ Gets New Chief
TikTok Steps Up European User Data Protections Amid Threats of Bans
Business Leaders Push Tech Agenda at China’s ‘Two Sessions’
China to Build 600,000 5G Base Stations in 2023
Xiaomi Goes Toe-to-Toe With Huawei in License, Patent Disputes
China Issues New Rules to Stamp Out Deceptive App Features
Chinese Regulators Question Auto Supplier Over Next-Generation Battery Claims
IQiyi Waters Down Plan to Cash In on Popular Feature After User Uproar
Guangzhou Commits $29 Billion to Local Tech Funds
Game Developer NetEase Teases Chatbot-Generated Dialogue for Mobile Release
China’s No. 2 Chipmaker Posts Record Quarterly Revenue, but Sees Slowing Growth
SMIC Warns of Difficult 2023 After Fourth Quarter Slowdown
Shanghai Bourse Probes AI Firms’ Stock Surge on Chatbot Fervor
NFTs, Metaverse Get Digital Cold Shoulder in Beijing
Baidu Talks Up ERNIE as China’s Answer to ChatGPT
Yangtze Memory Kicks Terminated Workers Out of Apartments
TuSimple Denies Media Report of U.S. Spying Probe
Robotics Firm UBTech Files for Hong Kong IPO
China Approves Older Novartis MS Drug

By Matthew Walsh / Jul 20, 2019 05:37 AM / Business & Tech

Photo: VCG

Photo: VCG

Novartis International AG won approval in China to sell its multiple sclerosis (MS) drug Gilenya, Reuters reports, deepening the Swiss pharmaceutical giant's business ties to the huge Chinese health care market and promising to shake up the treatment of what has traditionally been a poorly managed disease there.

MS is the most common autoimmune disease affecting the central nervous system. Around 30,000 people in China live with the condition, according to state news agency Xinhua. That compares with nearly 1 million people in the U.S. suffering the disease, according to a study by the National MS Society.

However, low awareness of MS in China means that the actual number of people with the disease may be significantly higher. In May, Chinese doctors urged both health-care professionals and the general public to learn more about the disease, adding that 95% of people knew nothing about MS before they were diagnosed.

MS occurs when the body’s immune system attacks the fatty sheaths around the nerves, disrupting their ability to send messages to one another. As MS progresses, it causes muscle and cognitive problems and can lead to lasting disabilities.

Although there is no one-size-fits-all cure, a number of treatments can significantly slow the progression of MS. China has long been playing catch-up with Western countries in rolling out such treatments, however, and comparatively few are yet available there.

One such drug, teriflunomide — sold under the trademark Aubagio — was approved by the U.S. Food and Drug Administration in 2012 but gained approval in China only last year.

Gilenya sales earned Novartis $825 million during the second quarter, making it the company’s second-largest source of revenue, Reuters said, adding that the drug has been available in the United States for almost a decade but is now being challenged by generic rivals, spurring Novartis’s push into other markets.

Related: In Depth: Why China’s Drug Review Revamp Is Stalling

Contact reporter Matthew Walsh (

Share this article
Open WeChat and scan the QR code